(VIANEWS) – Shares of SEQUANA MEDICAL (BEL 20: SEQUA.BR) fell by a staggering 33.53% in 21 sessions from €4.98 to €3.31 at 17:21 EST on Tuesday, following the last session’s downward trend. BEL 20 is dropping 1.3% to €3,756.47, after two successive sessions in a row of gains.
SEQUANA MEDICAL’s last close was €3.36, 55.2% below its 52-week high of €7.50.
About SEQUANA MEDICAL
Sequana Medical NV develops and commercializes treatment of fluid overload in liver disease, cancer, and heart failure. The company's products include alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; Direct Sodium Removal (DSR) for the treatment of persistent congestion due to heart failure; and alfapump DSR, a fully implanted system for direct sodium removal therapy in patients with fluid overload due to heart failure. It operates in Belgium, Germany, France, Switzerland, and internationally. The company was founded in 2006 and is headquartered in Ghent, Belgium.
Earnings Per Share
As for profitability, SEQUANA MEDICAL has a trailing twelve months EPS of €-1.33.
Moving Average
SEQUANA MEDICAL’s worth is way below its 50-day moving average of €4.92 and way below its 200-day moving average of €5.80.
Volatility
SEQUANA MEDICAL’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.72%, a negative 3.11%, and a positive 3.14%.
SEQUANA MEDICAL’s highest amplitude of average volatility was 2.36% (last week), 5.47% (last month), and 3.14% (last quarter).
Revenue Growth
Year-on-year quarterly revenue growth grew by 31.7%, now sitting on 922.69k for the twelve trailing months.
More news about SEQUANA MEDICAL (SEQUA.BR).
